|Bid||139.05 x 300|
|Ask||141.95 x 300|
|Day's Range||139.80 - 140.76|
|52 Week Range||110.76 - 144.35|
|PE Ratio (TTM)||24.45|
|Earnings Date||Jan 23, 2018|
|Forward Dividend & Yield||3.36 (2.40%)|
|1y Target Est||146.00|
Facebook is the best place to work in the United States according to the job website, Glassdoor. Other companies in the top 10 include Bain & Company, In-and-Out Burger and Google. Robert Hohman, CEO of Glassdoor, joins Yahoo Finance's Rick Newman to discuss how workers can leverage the tight job market and big data to their advantage.
Johnson & Johnson and Bayer were recently ordered by a Philadelphia court to pay $28 million in damages to an Indiana couple, related to internal bleeding about which the companies did not sufficiently warn patients.
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
The stakes are high as Johnson & Johnson seeks an appeals-court ruling tossing out a $151 million judgment over its Pinnacle artificial hips in a case that could foreshadow the outcome for thousands of ...
The primary endpoints was achieved on patients affected with Waldenström's macroglobulinemia at the end of the Phase 3 of the clinical trial
Dividend stocks and retirement investors go hand in hand. After all, retirement investing is all about income and with the days of living off of bond interest long gone, dividend stocks have taken up the mantle. Meanwhile, reinvested dividends offer higher compounding and downside protection.
The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the healthcare sector, rose 2.9% in November 2017.
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...
The jury slapped the companies, which jointly developed the blockbuster drug, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.
The jury slapped the companies, which jointly developed the blood thinner, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.
Johnson & Johnson’s immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company’s value, according to our estimates.
Johnson & Johnson and Bayer AG are responsible for a woman’s injuries tied to the blood-thinning drug Xarelto and must pay more than $29 million in damages, jurors concluded in the companies’ first loss ...